

Index

Legal cases and publications referred to in the text are in *italics*.

- A & M Records Inc. v Napster* 231, 233, 234, 236, 237, 251, 253
- AAAI 174
- abolition of patent system
negative economic effects on
international commercial
relations 21
- academic institutions
biomedical research and
development 123–4
commercial development of
discoveries made with federal
funds 141–2
incentives and rights for innovation
139, 149
interaction with government and
private sectors 118, 121, 126,
127–9, 130–33, 142, 143, 155, 156
licensing income 130
technology transfer 142, 143, 146
offices 139, 141–2
- Accelerating Access to AIDS drugs
Initiative (AAAI) 174
- access to medicines 28, 29, 170–71,
173, 174, 175, 183
partnerships with patent holders
175, 183
- ageing societies 162, 163
- Aghion, P. 106
- agriculture
competition law 345, 353
European regulation 352–3, 359
see also geographical indications
- Aimster* 253
- Arnst, C. 165–6
- Attaran, A. 172, 173
- Ayres, I. 258
- Bagwell, K. 103
- Barro, R. 106
- Bayh-Doyle Act (1980) 122, 139, 142,
143, 144, 146–7, 149, 153
- Benkler, Y. 255
- Berkowitz, L. 111
- Berkowitz, R. 177, 178
- Berne Convention (1886) 245, 259
- Bernheim, D. 103
- Bhagat, S. 111
- bilateral trade agreements 30, 31, 72–3,
307, 320, 325
see also geographical indications
- biomedical research and development
118
academic institutions, role of 123–4
government role 119, 125, 126
basic research and development
119, 120
creation of framework to encourage
research 120–22, 123
technology transfer 140–41
- interaction of academic, government
and private sectors 118, 121,
126, 127–9, 131, 133
examples of 131–3
- license agreements 118–19
- private-sector organizations
clinical trials 124–5
location of facilities near to
academic institutions 123–4
product development 124, 125
role of 124, 125
- Bishop, E. 20
- Black, F. 93
- Boyle, J. 245
- Breyer, Justice 231, 239, 240, 260
- Buchanan, J. 104
- C.B.S. Songs Ltd. & Ors v Amstrad
Consumer Electronics Plc. & Anor.*
235

- Chamberlin, E. 8
Chiron Corporation v Organon Teknika 197
- Cockburn, I. 126
- Colson, T. 111
- competition law 213, 214, 226, 227
 agricultural markets 345, 353
 geographical indications 351, 352, 354, 355, 356
 prohibited agreements 215
 compulsory licenses 171, 179, 180, 181, 182, 183, 218, 220, 223, 226, 227
- Conrad, J. 12, 13
Consten and Grundig v Commission 214
- consumer protection laws
 geographic origin of goods 348
 labelling 320, 348
 unfair competition 348
see also geographical indications
- consumer substitutes 251
- Cooperative Research Act (1984) 149–50
- Cooperative Research and Development Agreements (CRADAs) 122
- Copyright Act (1976) 270
- copyright law 160–61, 247, 268, 269
 access control 278, 279, 280, 281, 282, 284
 conflict with freedom of information 281, 282, 283
 communication rights 271, 272, 275, 276
 consumer substitutes 251
 contributory or secondary infringement 259
 copy protection devices 251
 developing countries
 impact on 29, 30
 future issues 284–5
 global definition of the standard of copyright 285
 inducement of infringement 237–8
 internet regulation 280–83
 justifications for 232, 240, 241
 balance between property as capital reward and the public domain 241, 242, 243
 ensuring fair and equal shares for all based on ethical grounds 243–4
 music industry 244, 245, 246–7
 new business models 251, 252, 253
 public domain 269–70, 283
 human rights 284
 reproduction rights 271, 272, 273–5
 shared monopolies
 effect on competition 253–5
 stakeholders 232
 corporate 249–50
 multilevel-creator 250–51
 single-creator 249
 technological measures 276, 277, 282, 283
 technology 230, 231, 245
 as driving force of copyright law 258, 259, 260
 example legal cases 232–40
see also file-sharing technology
- counterfeiting *see* violations of intellectual property rights
- CRADAs 122
- data protection
 deficiencies in 63
- de Bouftler, S. 3, 4
- Deardorff, A. 38
- designation of origin 300
 definition of 299
 protected designations of origin 300, 313, 347
see also geographical indications
- developing countries
 copyright
 problems of 29, 30
 foreign direct investment inflows 48, 49
 health care problems 163
 impact of intellectual property rights 5, 20–21
 imports of goods and services 48
 perspectives on the importance of intellectual property rights 47
 technology transfer 57, 58, 59
 acceptance of 39–40
 adoption of model laws 24
 implementation 24, 25
 pressure to comply with 24

- violations of intellectual property rights 65, 66, 67
- disease
 - cost of 166
 - prevalence of 163
- Doha Declaration 41–2, 179, 180–81, 183
- downstream markets 256, 257
- Drahos, P. 27
- Drug Price Competition and Patent Restoration Act (1984) 145
- Druker, B. 132
- DSM's Patent* 197
- EC *see* European Commission
- economic development
 - relationship with intellectual property rights 18, 19, 20, 21, 22, 23, 44, 45
- Economist* 3
- Eisenberg, R. 143
- enforcement of intellectual property rights 69, 70
 - costs of 38
 - dispute settlement mechanisms 74–5
- EU
 - guidebook 76
 - institutional cooperation within 76–7
 - outside EU borders 70
 - responsibility of individual Member States 69
 - strategy 70–77
- identification of priority countries 72
- joint initiatives 73
- multilateral and bilateral agreements 72–3
- obstacles to 67–8
- organizations' strategies 114
- political dialogue 73
- positive steps towards 68–9
- public awareness-raising 75, 76
- public–private partnerships 75
- technical cooperation 74
- see also* violations of intellectual property rights
- essential medicines 172
 - access to 170–71, 173, 174
 - partnerships with patent-holders 175, 183
 - extent of patenting in developing countries 172, 173, 183
 - prices of patented medicines 183
- European Commission (EC) 63
 - abuse of a dominant market position 217, 223, 224
 - refusal to licence 218, 219, 220, 221, 222, 223, 227
- Article 81 215, 225
- Article 82 217, 226, 227
- competition law 214, 226, 227
 - impact on intellectual property rights 213, 214
 - prohibited agreements 215
- innovation, encouragement of 224, 225, 226, 227
- negative sentiment about intellectual property rights 227
- technology licensing 215, 216
- Technology Transfer Block Exemption Regulation (TTBER) 215–16, 224, 225, 226
- Executive Orders 12591 and 12618 (1987) 151
- existence/exercise distinction 213–14
- Fahey, L. 111
- FDI *see* foreign direct investment
- Federal Technology Transfer Act (1986) 122, 140–41, 150–51, 153
- Field, B. 104
- File-sharing technology 233–5, 236–7, 238, 239, 240, 246–7, 251, 252, 253, 255
 - benefits of 255, 256, 257
 - stakeholders 259–60
- Finger, J. 41
- Fink, C. 53
- Firestone, O. 19
- food security 26, 27, 28
- Forbes 161
- foreign direct investment (FDI)
 - impact of intellectual property rights 23, 38, 49, 50, 51, 52, 53, 54, 58, 59
 - inflows to developing countries 48, 49
 - technology transfer, role in 48–9
- free-rider problem 106

- gene patents 188, 205, 206
 - claims to genes 188, 189, 190
 - criticisms of 203–4
 - industrial applicability 200, 201, 202, 203
 - inventive step
 - Europe 194–7
 - United States 198, 199
 - products of nature, as
 - Europe 191, 192
 - United States 193, 194
 - public policy concerns 199–200
 - utility, lack of 200, 201, 202, 203
- generics companies
 - access to drugs 145
 - entry into developing countries' markets 173, 174
 - prices of copy drugs 173, 174, 175, 183
- Genetech Inc's Patent* 192, 195, 196, 197
- genomics 133
 - collaboration of government, academia and industry 133
- geographical coverage of patent system 38
 - transferring wealth from the poor to the rich 39
- geographical indications (GIs) 8, 293, 294, 295, 305, 347
 - anti-competitive nature of 356, 358, 359, 360
 - authenticity of standards 350, 351
 - barrier to market entry 298
 - beneficiaries of 301, 302
 - bilateral and regional agreements 308, 335, 338
 - conflicting EU and US obligations 315
 - boundaries 351, 356, 357
 - collective nature of the protection 351
 - competition law
 - interface with 351, 352, 354, 355, 356
 - consortia administering of 354, 355, 356
 - definition of 293, 300
 - developing countries 301, 302
 - development and promotion of rural society, role in 298–9
 - divergent food cultures
 - problem of 358
 - economic impact of 297
 - EU bilateral agreements 314
 - accordance of automatic protection 315, 316
 - comparative analysis of 321–4
 - definition of geographical indications 321
 - elimination of TRIPS exceptions 316, 317, 322, 337
 - homonymous geographical indications 317
 - level and means of protection 315, 321, 336
 - mutual recognition 324, 337, 338
 - objectives of 314, 335
 - relationship with trademark protection 318, 323–4
 - scope of 337
 - structure of 314–15
 - traditional expressions 318, 319, 320, 323
 - EU system for the protection of 299, 300, 301, 312, 313
 - higher value markets
 - restriction of 359
 - history of 295–7
 - inappropriate registrations 356, 357
 - market definitions 355
 - migration of products 349–50, 357
 - multilateral register 295, 307
 - problems of 348, 349
 - protected geographical indications 300, 313, 347
 - shared character of 309–10
 - source of information for consumers 297
 - traditional knowledge, protection of 302
 - adoption and implementation of standards 306
 - continued and similar use of GIs 350
 - definition 293, 309, 310
 - exceptions 311, 312
 - levels of protection 310–11
 - scope of protection 310
 - US regional and bilateral agreements 325, 326, 327

- comparative analysis of 333–4
- definition and scope 327–8, 333, 337
- legal means of protection 328–9, 333, 335–6
- mutual protection clauses 331, 332, 334, 338
- objectives of 335
- procedural features 331, 334
- relationship with trademarks 329, 330, 334
- TRIPS exceptions 330, 331, 333, 337
- violations of 63
- wines and spirits 294, 311, 312
- see also* designation of origin
- Georgia-Pacific v U.S. Plywood-Champion Papers Inc.* 86
- Gillespie–White, L. 173
- Ginsburg, Justice 239, 260
- Gleevec 132
- government
 - biomedical research and development 119–23, 125, 126, 140–41
 - interaction with academic and private sectors 118, 121, 126, 127–9, 131–3
 - provision of intellectual property protection 133, 134
 - sponsored research
 - policy issues 143–4
 - title to inventions 144–5, 149
 - technology transfer 140–41
- Greater Access to Affordable Pharmaceuticals Act (GAAP) 145
- Grossman, G. 33, 106

- Hall, B. 111
- Hansen, F. 111
- Hatch-Waxman Act (1984) 145
- Hay, J. 165
- health care
 - financing of 164
- Helpman, E. 106
- Henderson, R. 126
- Hoffman, Lord 189, 206
- Howard Florey Institutel Relaxin* 191, 199, 201
- Howitt, P. 106
- Hume, D. 242

- ICI and CSC v Commission* (Commercial Solvents case) 218–19, 224
- ICOS Corporation* 192, 202
- imatinib mesylate 131–2
- imitation of ideas
 - disincentive to innovate 106
- implementation costs of IPR
 - agreements 47
- IMS Health v NDC Health* 221, 222, 223, 226, 254
- In re Bell* 198
- In re Deuel* 198
- In re Wallach* 199
- incentive to disclose secrets 3–4
- industrial significance of patent protection 19
- innovation subsidy policy 107
- innovative firms 109, 111
- Intellectual Property Institute (IPI) 204
- intellectual property rights (IPRs)
 - forms of 362–3
 - framework for studying 361, 362, 363
 - history of 363
 - impact of 361
- internet
 - regulation of 279, 280
 - copyright 280–83
- IPRs *see* intellectual property rights

- Jones, C. 45, 106

- Kazaa 236
 - see also* file-sharing technology
- Kearney, A. 54
- Khan, A. 7
- Killinger, S. 103
- Kirin-Amgen Inc and others v Transkaryotic Therapies Inc and others* 188, 192, 194, 195, 206
- Kline, D. 111
- knowledge
 - excludability of, 106–7
 - investments in 109
 - high fixed costs of production 106
 - low marginal costs of production 106
 - non-rival nature of 106, 107
 - product life-cycle curve 109, 110

- knowledge-based growth (KBG) 105,
 106, 107
 patents as dominant policy
 instrument 108
 'knowledge commons' 143
 Kortum, S. 111
- Lamberton, D. 20
 Lamy, P. 173
 Lang, J. 111
 Lanjouw, J. 111, 114
 Laramie, A. 104
 large organizations
 long-term patent strategies 111, 112,
 113
 patent enforcement strategies 114
 resources available for patent
 applications 112–13
 timing of patent filings 113–14
 Lee, J.-Y. 53
 Lerner, J. 111, 114
 Lessig, L. 245
 licensing 54–5, 56, 57, 58, 59, 154, 215,
 216
 academic institutions
 licensing income 130
 between private companies 129, 130
 biomedical research and
 development 118–19
 compulsory licenses 171, 179, 180,
 181, 182, 183, 218, 220, 223,
 226, 227
 provisions in license agreements 127,
 154
 royalty payments 128, 129
 technology transfer 54, 55, 56, 127,
 128, 129, 133
 valuations 84
 Lippoldt, D. 44, 46, 47, 49, 50, 51, 52,
 53, 54, 55, 56, 57
 Litman, J. 255, 256
 Llewellyn, D. 19
 local reputations 296
 see also geographical indications
 Locke, J. 240, 241, 242, 243
- Macfie, R. 3
 Machlup, F. 2, 3, 4, 5, 6, 19, 363
 Macleod, H. 3
 Mair, D. 104
 Mandeville, T. 20
 Mansfield, E. 19, 53, 88
 market power 217–18
 Maskus, K. 44, 55, 56
 material transfer agreements (MTAs)
 154–5
 reach-through provisions 155
 Matthews, D. 111
 McCain, J. 145
 medical technology
 access to 165
 Merges, R. 111, 112
Metro-Goldwyn-Mayer Studios Inc. v
Grokster Ltd 230, 231, 236, 237,
 238, 240, 253, 255, 256, 257, 260,
 261
 Michelangelo, B. 249
Microsoft 223–4, 226, 227, 257–8
 Mill, J. 168
 monopolies 1, 175
Monsanto Canada, Inc. v. Schmeiser
 26–7
 Moran, W. 299
 Murtha, E. 81
 music industry
 copyright law 244, 245
 P2P services 246–7
 technological protection measures
 246
 new technologies 244, 245, 251, 252,
 253
 Music Publishers Association 259
- Nalebuff, B. 258
 National Academies Press 198
 National Competitiveness Technology
 Transfer Act (1989) 152
 National Institute of Standards and
 Technology Authorization Act
 (1989) 151–2
 National Institutes of Health (NIH)
 153
 grants 155–6
 natural property right in ideas 2–3
 Nelson, R. 112
 new business models 251, 252, 253
 NIH *see* National Institutes of Health
 Nogues, J. 41
 Nowell, P. 131
 Nunnenkamp, P. 53

- OECD 45, 49, 54, 298
 Olewiler, N. 104
 Omnibus Trade and Competitiveness Act (1988) 151
 Organization for Economic Co-operation and Development (OECD) 45, 49, 54, 298
 organized innovation 6–7
 Orphan Drug Act (1983) 161
- P2P technology *see* file-sharing technology
 paclitaxel 132
 Palda, F. 104
 parallel importation 171, 181, 182
 counterfeit and substandard drugs 181
 Park, W. 44, 46, 49, 50, 51, 52, 53, 54, 55, 56, 57
Parke-Davis v HK Mulford 194
 patents 153, 154
 applications 112
 resources available for 112–13
 as charge for knowledge 36
 claims 153
 dissemination of information 107–8
 drivers for 111, 112
 exception from monopolies 1
 historical debates over patent protection 2, 3, 4, 5, 6
 incentives to innovate 107–8
 infringements of 63
 need for
 when inventions cannot be kept secret 34–5
 organizations' strategies 111, 112, 113
 social impacts of 35, 36, 38
 specification 153
 terms 37–8
 timing of patent filings 113, 114
 tradeoff between public and private benefit 160
 PDOs 300, 313, 347
 Peer-to-peer (P2P) technology *see* file-sharing technology
 Penrose, E. 2, 3, 6, 363
 Persson, T. 103
 PGIs 300, 313, 347
 pharmaceutical industry
 extent of research and development 165
 global differential pricing systems 182
 incremental innovation 176, 177
 intellectual property rights 159–60, 164, 165, 166, 167, 168
 data protection 161
 impact on prices in developing countries 177–8, 183
 orphan drugs 161–2
 patent life 177
 patent term extension 161
 proposed global agreement 167
 monopoly pricing power 175, 176, 177, 183
 pharmaceutical products
 financial burden borne by private sector 163–4
 financing the development of 42
 free-riding countries 167
 therapeutic competition 176, 177, 183
Philips v Ingman 220
 Pickering, F. 111
Pioneer Hi-Bred International Inc. v J.E.M. Ag Supply Inc. 26
 piracy *see* violations of intellectual property rights
 Plant, A. 4, 8
 plant variety protection 26, 27, 28
 Polanyi, M. 4
 pricing 161
 Primo Braga, C. 53
 private goods 36
 private property rights 36
 private sector
 biomedical research and development 123–5, 126, 127
 interaction with academic and government sectors 118, 121, 126, 127–9, 131–3, 142, 143
 licensing between companies 129, 130
 source of patented technologies to academic institutions 131
 sponsorship of research 130–31, 155, 156
 protected designations of origin (PDOs) 300, 313, 347

- protected geographical indications (PGIs) 300, 313, 347
- Prusak, L. 111
- public goods 36
financing the production of 36–7
governmental provision of 37
- Recording Indus. Association of America, Inc. v Diamond Multimedia Systems Inc.* 233
- regional trade agreements (RTAs) 47, 307, 320, 325
see also geographical indications
- Ricardo, J. 3
- rights holders
importance of intellectual property rights 45, 46
- Rivette, K. 111
- Roberts, K. 104
- Rogers, J. 4
- Romer, P. 106
- Romer, T. 104
- Rothschild, R. 111
- Rousseau, J.-J. 4
- Rozek, R. 177, 178
- RTAs *see* regional trade agreements
- RTE and ITP v Commission* (Magill case) 219–20, 222, 223, 224, 226, 254
- Sala-i-Martin, X. 106
- scale neutrality of intellectual property
policy instruments 103, 104, 105, 114–15
drivers for patenting intellectual assets 111, 112
patent enforcement strategies 114
resources available for patent applications 112, 113
timing of patent filings 113, 114
- Schankerman, M. 111
- Schechter, F. 8
- Scholes, M. 93
- Schumer, C. 144, 145
- Schwartz, M. 88
- secondary markets 256, 257
- Securities Data Corporation 56
- Shapiro, C. 33
- Silbertson, Z. 19
- Small Business Innovation Development Act (1982) 149
- small organizations
patent enforcement strategies 114
resources available for patent applications 113
short-term patent strategies 112
timing of patent filings 113
- Smarzynska, B. 53
- Smith, A. 354
- Smith, M. 111
- social contract 4
- social progress 3
- Somaya, D. 114
- Sony Corp. v Universal Studios Inc.* 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 257, 259
- Space-shifting activities 233
- Spatz, J. 53
- sponsored research 130–31, 143, 144, 145, 149, 155, 156
- stakeholders 232, 248
corporate 249–50
multilevel-creator 250–51
primary 248
secondary 248
single-creator 249
- Statute of Anne (1710) 245
- Statute of Monopolies 1
- Stevenson–Wylder Technology Innovation Act (1980) 139, 149
- Sunday Telegraph* 356
- survival rates 165, 166
- Tabellini, G. 103
- targeted treatment 166
- Taxol 132
- Taylor, C. 19
- technical designs
infringements of 63
- technology
copyright law 230, 231
as driving force of 258, 259, 260
example cases 232–40
time and 258, 259
see also technology transfer
- technology transfer 21, 39, 146
academic institutions 142, 143, 146

- developing countries
 - influence of intellectual property rights 57, 58, 59
 - need for complementary conditions 58–9
- foreign direct investment, role of 48–9
- government sector 140–41
- government sponsored research
 - policy issues 143–4
 - title to inventions 144–5, 149
- interaction of academic and private sector 126–7, 142, 143
- legislation 149–52
- licensing 54, 55, 56, 127, 128, 129, 133
- market forces 133, 134
- offices 139, 141–2
- trade as a vehicle for 47, 48
- Teece, D. 109, 111
- theft of intellectual property
 - concern of businesses 54
- Thomas, Judge 230
- Tiercé Ladbroke v Commission* 221, 223
- time-shifting activities 232, 235
- timing of a patent filing 113–14
- Tizzano, Advocate General 222
- Toole, A. 131
- trade
 - influence of intellectual property rights 49, 50, 51, 53, 58, 59
- trade-related aspects of intellectual property rights (TRIPS)
 - agreement 5–6, 17, 18, 40, 41, 46–7, 178, 348
 - amendments to 41, 42
 - beneficiaries of 22
 - compulsory licenses 179, 180
 - copyright 30
 - counterfeit medicines 180
 - countries' differing stances 305
 - developing countries
 - acceptance of 39–40
 - adoption of model laws 24
 - implementation 24, 25
 - pressure to comply 24
 - enforcement of intellectual property rights 72, 73
 - expenses of 41
 - geographical indications 293, 294, 295, 305, 308, 318
 - adoption and implementation of standards 306
 - continued and similar use of GIs 350
 - definition of 293, 309, 310
 - EU elimination of exceptions 316, 317, 322, 337
 - exceptions 311, 312
 - levels of protection 310–11
 - multilateral register 295, 307
 - scope of protection 310
 - wines and spirits 294, 311, 312
 - impact on access to medicines and public health 178–9, 183
 - institutional costs of compliance 25–6
 - review agenda 22, 25
 - technology transfer objectives 21
 - traditional expressions 319, 320
 - transfer of wealth from poor to rich 33, 39
 - see also* Doha Declaration
- Trademark Clarification Act (1984) 150
- trademarks 8, 160
 - violations of 63
 - see also* geographical indications
- traditional expressions 318, 319, 320, 323
- traditional knowledge 302
- Trajtenberg, M. 111
- TRIPS agreement *see* trade-related aspects of intellectual property rights agreement
- UK Commission on Intellectual Property Rights 23
- United Nations Conference on Trade and Development (UNCTAD) 5, 19, 25
- United States
 - access to generic drugs 145
 - bilateral and regional agreements 320, 325
 - preference for 30, 31
 - government funding for science and technology 140

- state-sponsored agricultural certification programmes 346
 - see also* geographical indications
 - Universal City Studios v Reimerdes* 278
- universities *see* academic institutions
- US Patent and Trademark Office 346
- valuation of intellectual property 67, 81, 83, 99
 - accounting standards, compliance with 85
 - acquisitions 84
 - bankruptcy proceedings 86–7
 - business decisions 83–4
 - consistency in valuations 87
 - cost approach 82
 - divestitures 84
 - holding of patents 84
 - importance of 111
 - income approach 81, 83, 87–8, 99
 - discounted cash flow (DCF) method 81, 88–9, 90, 97, 98, 99
 - real option method 81, 89, 91–7, 99
 - licensing transactions 84
 - litigation 86
 - market approach 82–3
 - patents as a proxy for 111
 - spin-offs 84
 - tax regulations, compliance with 85, 86
 - venture capital financing 85
- Vernon, R. 4, 5
- violations of intellectual property rights 63
 - criminal organizations, involvement of 65
 - developed countries, effect on 64–5
 - developing countries, effect on 65, 66, 67
 - health and consumer protection 64–5
 - impact on trade 17, 18, 62
 - need for comprehensive policy to tackle 66, 67
 - tax revenues, effect on 65
 - types of 63
 - see also* enforcement of intellectual property rights
 - Volvo v Veng* 219, 220
 - von Justi, J. 168
- Wagner, S. 88
- wealthier countries
 - impact of intellectual property rights 47
- Weidenbaum, M. 103
- Wertheimer, A. 176
- WHO 164, 171, 172, 174–5
- WIPO *see* World Intellectual Property Organization
- Wolowski, L. 4
- World Health Organization (WHO) 164, 171, 172, 174–5
- World Intellectual Property Organization (WIPO) 18, 19
 - international IPR agreements 46, 246
- World Trade Organization (WTO) 45, 46, 47, 180, 183
 - developing countries' view of 33
 - see also* trade-related aspects of intellectual property rights agreement
- Zahra, S. 111